S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   383.13 (-1.74%)
AAPL   161.84 (-1.17%)
MSFT   323.01 (-1.97%)
FB   306.84 (-1.14%)
GOOGL   2,840.03 (-0.67%)
AMZN   3,389.79 (-1.38%)
TSLA   1,014.97 (-6.42%)
NVDA   306.93 (-4.46%)
BABA   111.96 (-8.23%)
NIO   32.15 (-11.19%)
CGC   9.99 (-3.57%)
AMD   144.01 (-4.43%)
GE   92.77 (-2.58%)
MU   81.62 (-1.52%)
T   23.46 (+1.78%)
F   19.14 (-3.67%)
DIS   146.22 (-0.67%)
PFE   54.27 (+2.32%)
AMC   29.01 (-4.19%)
ACB   5.82 (-5.21%)
BA   198.49 (-1.92%)
S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   383.13 (-1.74%)
AAPL   161.84 (-1.17%)
MSFT   323.01 (-1.97%)
FB   306.84 (-1.14%)
GOOGL   2,840.03 (-0.67%)
AMZN   3,389.79 (-1.38%)
TSLA   1,014.97 (-6.42%)
NVDA   306.93 (-4.46%)
BABA   111.96 (-8.23%)
NIO   32.15 (-11.19%)
CGC   9.99 (-3.57%)
AMD   144.01 (-4.43%)
GE   92.77 (-2.58%)
MU   81.62 (-1.52%)
T   23.46 (+1.78%)
F   19.14 (-3.67%)
DIS   146.22 (-0.67%)
PFE   54.27 (+2.32%)
AMC   29.01 (-4.19%)
ACB   5.82 (-5.21%)
BA   198.49 (-1.92%)
S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   383.13 (-1.74%)
AAPL   161.84 (-1.17%)
MSFT   323.01 (-1.97%)
FB   306.84 (-1.14%)
GOOGL   2,840.03 (-0.67%)
AMZN   3,389.79 (-1.38%)
TSLA   1,014.97 (-6.42%)
NVDA   306.93 (-4.46%)
BABA   111.96 (-8.23%)
NIO   32.15 (-11.19%)
CGC   9.99 (-3.57%)
AMD   144.01 (-4.43%)
GE   92.77 (-2.58%)
MU   81.62 (-1.52%)
T   23.46 (+1.78%)
F   19.14 (-3.67%)
DIS   146.22 (-0.67%)
PFE   54.27 (+2.32%)
AMC   29.01 (-4.19%)
ACB   5.82 (-5.21%)
BA   198.49 (-1.92%)
S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   383.13 (-1.74%)
AAPL   161.84 (-1.17%)
MSFT   323.01 (-1.97%)
FB   306.84 (-1.14%)
GOOGL   2,840.03 (-0.67%)
AMZN   3,389.79 (-1.38%)
TSLA   1,014.97 (-6.42%)
NVDA   306.93 (-4.46%)
BABA   111.96 (-8.23%)
NIO   32.15 (-11.19%)
CGC   9.99 (-3.57%)
AMD   144.01 (-4.43%)
GE   92.77 (-2.58%)
MU   81.62 (-1.52%)
T   23.46 (+1.78%)
F   19.14 (-3.67%)
DIS   146.22 (-0.67%)
PFE   54.27 (+2.32%)
AMC   29.01 (-4.19%)
ACB   5.82 (-5.21%)
BA   198.49 (-1.92%)
NASDAQ:APTX

Aptinyx Stock Forecast, Price & News

$2.15
-0.13 (-5.70%)
(As of 12/3/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.11
$2.31
50-Day Range
$2.11
$2.50
52-Week Range
$2.10
$4.73
Volume
172,947 shs
Average Volume
562,983 shs
Market Capitalization
$145.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.32
30 days | 90 days | 365 days | Advanced Chart
Receive APTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptinyx and its competitors with MarketBeat's FREE daily newsletter.


Aptinyx logo

About Aptinyx

Aptinyx Inc. is a clinical stage biopharmaceutical company. It engages in the discovery, development, and commercialization of transformative therapies for disorders of the brain and nervous system. Its product includes NYX-2925, NYX-783, NYX-458, and the AGN-241751 program. The company was founded by Norbert G. Riedel and Joseph R. Moskal in June 2015 and is headquartered in Evanston, IL.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:APTX
Fax
N/A
Employees
34
Year Founded
N/A

Sales & Book Value

Annual Sales
$1.56 million
Book Value
$2.31 per share

Profitability

Net Income
$-50.05 million
Pretax Margin
-6,676.40%

Debt

Price-To-Earnings

Miscellaneous

Free Float
62,339,000
Market Cap
$145.59 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/09/2021
Today
12/03/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/23/2022

MarketRank

Overall MarketRank

2.33 out of 5 stars

Medical Sector

257th out of 1,390 stocks

Pharmaceutical Preparations Industry

110th out of 668 stocks

Analyst Opinion: 3.3Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -












Aptinyx (NASDAQ:APTX) Frequently Asked Questions

Is Aptinyx a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptinyx in the last twelve months. There are currently 1 sell rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Aptinyx stock.
View analyst ratings for Aptinyx
or view top-rated stocks.

How has Aptinyx's stock price been impacted by COVID-19 (Coronavirus)?

Aptinyx's stock was trading at $2.43 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, APTX shares have decreased by 11.5% and is now trading at $2.15.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Aptinyx?

Aptinyx saw a decrease in short interest in November. As of November 15th, there was short interest totaling 468,400 shares, a decrease of 20.0% from the October 31st total of 585,600 shares. Based on an average trading volume of 162,400 shares, the days-to-cover ratio is currently 2.9 days. Approximately 1.5% of the shares of the stock are sold short.
View Aptinyx's Short Interest
.

When is Aptinyx's next earnings date?

Aptinyx is scheduled to release its next quarterly earnings announcement on Wednesday, March 23rd 2022.
View our earnings forecast for Aptinyx
.

How were Aptinyx's earnings last quarter?

Aptinyx Inc. (NASDAQ:APTX) announced its quarterly earnings data on Tuesday, November, 9th. The company reported ($0.31) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.31). During the same quarter in the previous year, the company posted ($0.24) EPS.
View Aptinyx's earnings history
.

What price target have analysts set for APTX?

4 analysts have issued 12 month price targets for Aptinyx's shares. Their forecasts range from $8.00 to $8.00. On average, they expect Aptinyx's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 272.1% from the stock's current price.
View analysts' price targets for Aptinyx
or view top-rated stocks among Wall Street analysts.

Who are Aptinyx's key executives?

Aptinyx's management team includes the following people:
  • Norbert G. Riedel, Chief Executive Officer & Director
  • Andrew Kidd, President & Chief Operating Officer
  • Ashish Khanna, Chief Financial & Business Officer
  • Harald Murck, Vice President-Clinical & Medical Affairs
  • Kathryn King, Senior Vice President-Clinical & CMC Operations

What other stocks do shareholders of Aptinyx own?

When did Aptinyx IPO?

(APTX) raised $77 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 5,300,000 shares at $14.00-$15.00 per share. J.P. Morgan, Cowen, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

What is Aptinyx's stock symbol?

Aptinyx trades on the NASDAQ under the ticker symbol "APTX."

Who are Aptinyx's major shareholders?

Aptinyx's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Millennium Management LLC (1.54%), Renaissance Technologies LLC (0.70%), Two Sigma Advisers LP (0.37%), Morgan Stanley (0.32%), Dimensional Fund Advisors LP (0.17%) and Raymond James & Associates (0.17%). Company insiders that own Aptinyx stock include Adam Koppel, Adams Street Partners Llc, Bain Capital Life Sciences Inv, Norbert G Riedel, Rachel E Sherman and Robert J Hombach.
View institutional ownership trends for Aptinyx
.

Which institutional investors are selling Aptinyx stock?

APTX stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Two Sigma Advisers LP, Millennium Management LLC, Morgan Stanley, Dimensional Fund Advisors LP, Two Sigma Investments LP, Squarepoint Ops LLC, and Citadel Advisors LLC.
View insider buying and selling activity for Aptinyx
or view top insider-selling stocks.

How do I buy shares of Aptinyx?

Shares of APTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aptinyx's stock price today?

One share of APTX stock can currently be purchased for approximately $2.15.

How much money does Aptinyx make?

Aptinyx has a market capitalization of $145.59 million and generates $1.56 million in revenue each year. The company earns $-50.05 million in net income (profit) each year or ($1.02) on an earnings per share basis.

How many employees does Aptinyx have?

Aptinyx employs 34 workers across the globe.

What is Aptinyx's official website?

The official website for Aptinyx is www.aptinyx.com.

Where are Aptinyx's headquarters?

Aptinyx is headquartered at 909 DAVIS STREET SUITE 600, EVANSTON IL, 60201.

How can I contact Aptinyx?

Aptinyx's mailing address is 909 DAVIS STREET SUITE 600, EVANSTON IL, 60201. The company can be reached via phone at (847) 871-0377 or via email at [email protected].


This page was last updated on 12/3/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.